Summary: Axsome Therapeutics In. is set to present multiple studies on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society. These presentations include topline results from the phase 3 SYMPHONY trial of AXS-12 for narcolepsy, findings from the CRESCENDO survey on the unmet needs of type 1 narcolepsy patients, and previously reported data on solriamfetol showing improvements in cognitive function and wakefulness for patients with excessive daytime sleepiness (EDS) related to obstructive sleep apnea (OSA) and narcolepsy.
Three Key Takeaways:
- Phase 3 SYMPHONY Trial Results for AXS-12 – Axsome will present the topline results of its phase 3 SYMPHONY trial, highlighting the efficacy of AXS-12 for treating narcolepsy, including key data on symptom management.
- Unmet Needs in Narcolepsy – The CRESCENDO survey will underscore the significant unmet needs in patients with type 1 narcolepsy, focusing on symptom burden and quality of life.
- Solriamfetol Shows Cognitive Benefits – Presentations on solriamfetol will include data demonstrating its ability to improve cognitive function and wakefulness in patients with excessive daytime sleepiness associated with OSA and narcolepsy.
Axsome Therapeutics Inc announced seven presentations on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society, being held Sept 24-27, in Seville, Spain.
Featured presentations include data from the SYMPHONY phase 3 trial of AXS-12 in narcolepsy, findings from the CRESCENDO patient survey underscoring the unmet needs of patients with type 1 narcolepsy, and previously reported data on solriamfetol demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with OSA and narcolepsy.
Details for the presentations are as follows:
AXS-12:
- Title: AXS-12 for the Treatment of Narcolepsy: Topline Results from the Phase 3 SYMPHONY Trial
- Poster Presentation Date and Time: Wednesday, Sept 25, 12:15 – 1:15 pm and 4 – 5:45 pm CEST
- Lead Author: Michael Thorpy, MD, director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and professor of neurology at Albert Einstein College of Medicine, New York, NY, USA
- Poster Number: P254
- Title: CRESCENDO: Results from a Survey of Symptom Burden and Quality of Life in Patients with Narcolepsy Type 1
- Poster Presentation Date and Time: Wednesday, Sept 25, 12:15 – 1:15 pm and 4 – 5:45 pm CEST
- Lead Author: Michael Thorpy, MD, director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and professor of neurology at Albert Einstein College of Medicine, New York, NY, USA
- Poster Number: P265
Solriamfetol:
- Title: Solriamfetol and Maintenance of Wakefulness Outcomes in Patients with Narcolepsy and Obstructive Sleep Apnea
- Oral Presentation Date and Time: Tuesday, Sept 24, 9:55 – 10:01 am CEST
- Poster Presentation Date and Time: Wednesday, Sept 25, 12:15 – 1:15 pm and 4 – 5:45 pm CEST
- Lead Author: Michael Thorpy, MD, director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and professor of neurology at Albert Einstein College of Medicine, New York, NY, USA
- Poster Number: P475
- Title: Effects of Solriamfetol on Cognition in Patients with Excessive Daytime Sleepiness Associated with Narcolepsy
- Poster Presentation Date and Time: Wednesday, Sept 25, 12:15 – 1:15 pm and 4 – 5:45 pm CEST
- Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany
- Poster Number: P197
- Title: Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression
- Poster Presentation Date and Time: Friday, Sept 27, 10:45 am – 1:30 pm CEST
- Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany
- Poster Number: P198
- Title: SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcome
- Poster Presentation Date and Time: Thursday, Sept 26, 12 – 1:30 pm and 5:30 – 6:45 pm CEST
- Lead Author: Samantha Floam, DMD, Axsome Therapeutics
- Poster Number: P799
- Title: Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition
- Poster Presentation Date and Time: Friday, Sept 27, 10:45 am – 1:30 pm CEST
- Lead Author: Hans Van Dongen, PhD, professor at Washington State University
- Poster Number: P1248
ID 329231250 | Ai © Pachariya88 | Dreamstime.com
Leave a Reply